文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

KRAS突变肺腺癌脑转移患者立体定向放疗的颅内控制与生存

Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic Radiosurgery.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-02-08

本研究纳入195例2014至2018年接受立体定向放疗的KRAS突变肺腺癌脑转移患者,随访至2022年或死亡。中位随访11个月,中位总生存27.7个月,颅内无进展生存22.1个月;KEAP1/STK11共突变与较差总生存相关,KRAS G12C与非G12C突变患者结局相似。

要点

  • 中位总生存27.7个月,颅内无进展生存22.1个月,12和24个月病灶局部控制率分别为89.9%和87.5%。
  • KEAP1/STK11共突变与较差总生存相关(HR 1.94),但与颅内无进展生存无关。
  • KRAS G12C与非G12C突变患者颅内无进展生存、总生存及颅内进展事件类型无差异。

核心结论

  • KRAS与KEAP1/STK11共突变与较差总生存相关,但与颅内无进展生存无关;KRAS G12C与非G12C突变患者接受立体定向放疗后结局相似。

研究设计与样本

  • 单中心回顾性研究,纳入195例2014至2018年接受立体定向放疗的KRAS突变肺腺癌脑转移患者,随访至2022年或死亡。

主要发现

  • 中位随访11个月,中位总生存27.7个月(95%CI 19.7-36.8),中位颅内无进展生存22.1个月(95%CI 16.8-48.9)。
  • 12和24个月病灶局部控制率分别为89.9%和87.5%。
  • 多变量Cox回归中,KEAP1/STK11共突变(HR 1.94,95%CI 1.04-3.62,q=0.087)、进展性颅外疾病(HR 3.41,95%CI 1.38-8.39,q=0.087)、混合缓解颅外疾病(HR 3.52,95%CI 1.2-10.3,q=0.092)及诊断时脑转移≥6个(HR 2.58,95%CI 1.22-6.63,q=0.087)与较差总生存相关。
  • 程序性死亡配体1阳性与改善的总生存相关(HR 0.57,95%CI 0.37-0.87,P=0.01)。
  • 立体定向放疗前化疗(HR 2.69,95%CI 1.42-5.09,q=0.04)和年龄>65岁(HR 2.21,95%CI 1.25-3.93,q=0.055)与较差的颅内无进展生存相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Precision medicine according to molecularly defined subgroups offers great potential to improve outcomes for patients with metastatic lung adenocarcinoma. This study describes clinical outcomes and the impact of co-occurring genetic alterations on outcomes following stereotactic radiosurgery (SRS) among patients with Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant lung adenocarcinoma. METHODS AND MATERIALS: A total of 195 patients with KRAS-mutant lung adenocarcinoma were treated with SRS for brain metastases (BMs) between 2014 and 2018 with follow-up until 2022 or death. Coprimary outcomes were median overall survival (OS) and intracranial progression-free survival (iPFS); univariable and multivariable Cox regression models and Kaplan-Meier survival analysis were used. RESULTS: Median follow-up from the date of BM diagnosis was 11 months. Median OS and iPFS for the cohort were 27.7 months (95% CI, 19.7-36.8) and 22.1 months (95% CI, 16.8-48.9), respectively. Lesion-level local control at 12 and 24 months was 89.9% and 87.5%, respectively. In a multivariable Cox regression model, inferior OS was associated with coalterations in KEAP1 and STK11 (hazard ratio [HR], 1.94; 95% CI, 1.04-3.62; q = 0.087), progressive (HR, 3.41; 95% CI, 1.38-8.39; q = 0.087), and mixed response (HR, 3.52; 95% CI, 1.2-10.3; q = 0.092) extracranial disease, and 6 or more BMs at time of diagnosis (HR, 2.58; 95% CI, 1.22-6.63; q = 0.087). Positive programmed death ligand 1 status was associated with improved OS (HR, 0.57; 95% CI, 0.37-0.87; P = .01). Inferior iPFS was associated with chemotherapy before SRS (HR, 2.69; 95% CI, 1.42-5.09; q = 0.04) and age >65 years (HR, 2.21; 95% CI, 1.25-3.93; q = 0.055). KRAS G12C was not associated with differences in iPFS, OS, or type of intracranial progression event following SRS. CONCLUSIONS: Coalteration of KRAS and KEAP1/STK11 was associated with inferior OS, but not iPFS. Similar outcomes were found in patients harboring KRAS G12C and non-G12C mutant non-small cell lung cancer BMs. Further understanding of molecularly characterized subgroups will be critical in driving personalized radiation therapy for patients with lung cancer BMs.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gaeta B, Eichholz JE, Walch H, et al. Intracranial Disease Control and Survival among Patients with KRAS-mutant Lung Adenocarcinoma and Brain Metastases Treated with Stereotactic Radiosurgery. Int J Radiat Oncol Biol Phys. 2025. PMID: 39929348. doi:10.1016/j.ijrobp.2025.01.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。